Literature DB >> 2592981

Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity.

A Elderson1, R Gerritsen van der Hoop, W Haanstra, J P Neijt, W H Gispen, F G Jennekens.   

Abstract

In 20 ovarian cancer patients treated by cisplatin-based chemotherapy quantitative investigations of the vibration and the thermoperception were performed. Following the administration of cisplatin of 300 mg/m2 and more the vibration perception threshold (VPT) was shown to be significantly elevated in all patients, despite the absence of clinical symptoms and signs in a number of patients. The VPT returned within 8 months to its original level in the 2 patients who were followed after cessation of therapy (cumulative dose of cisplatin 450-525 mg/m2). The changes seen in hands and in feet were comparable. There was no significant difference between the left and the right hand side. Thermoperception thresholds did not change during the treatment period. This study shows that quantitative measurement of vibration perception thresholds in patients treated with cisplatin is a relatively simple, accurate and reliable technique. Measurement is only required at the hand. It is concluded that this technique is a valuable tool in the assessment of cisplatin neurotoxicity and may be used in the monitoring of drugs that claim to be of benefit in the prevention and treatment of this affliction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2592981     DOI: 10.1016/0022-510x(89)90187-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

1.  The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.

Authors:  A Hovestadt; M E van der Burg; H B Verbiest; W L van Putten; C J Vecht
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

2.  Cisplatin-induced autonomic neuropathy: does it really exist?

Authors:  W P Vandertop; W B de Vries; N C Notermans; M J Nijsen; D J de Wildt; C A Tulleken; W H Gispen
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

3.  An 18-month follow-up study on vibrotactile sense, muscle strength and symptoms in computer users with and without symptoms.

Authors:  M Pilegaard; B R Jensen
Journal:  Int Arch Occup Environ Health       Date:  2005-06-14       Impact factor: 3.015

4.  Preventing chemotherapy-induced neuropathy.

Authors:  K L Nudleman
Journal:  West J Med       Date:  1991-07

5.  Involvement of the peripheral nervous system in primary Sjögren's syndrome.

Authors:  P J Barendregt; M J van den Bent; V J van Raaij-van den Aarssen; A H van den Meiracker; C J Vecht; G L van der Heijde; H M Markusse
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

Review 6.  Interventions for preventing neuropathy caused by cisplatin and related compounds.

Authors:  James W Albers; Vinay Chaudhry; Guido Cavaletti; Ross C Donehower
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 7.  Sensory neuropathies including painful and toxic neuropathies.

Authors:  J H Wokke; G W van Dijk
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

8.  A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.

Authors:  M J McKeage; P Mistry; J Ward; F E Boxall; S Loh; C O'Neill; P Ellis; L R Kelland; S E Morgan; B Murrer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

10.  Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.

Authors:  F P Hamers; C Pette; B Bravenboer; C J Vecht; J P Neijt; W H Gispen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.